Tirzepatide was noninferior to dulaglutide in reducing a composite of cardiovascular events in people with type 2 diabetes and existing heart disease.Both agents are currently approved for type 2 diabetes, …
Copyright MatchingDonors.com©️ 2025 All rights reserved.